Cencora, Inc. (NYSE:COR) Shares Bought by Pflug Koory LLC

Pflug Koory LLC increased its position in shares of Cencora, Inc. (NYSE:COR) by 6.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,160 shares of the company’s stock after buying an additional 75 shares during the period. Pflug Koory LLC’s holdings in Cencora were worth $261,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Concord Wealth Partners purchased a new stake in shares of Cencora during the 3rd quarter worth $30,000. Householder Group Estate & Retirement Specialist LLC boosted its position in shares of Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock worth $33,000 after acquiring an additional 69 shares in the last quarter. Ashton Thomas Securities LLC purchased a new position in shares of Cencora in the 3rd quarter valued at about $41,000. Modus Advisors LLC acquired a new stake in shares of Cencora during the 4th quarter worth about $54,000. Finally, Carolina Wealth Advisors LLC lifted its stake in Cencora by 366.7% during the third quarter. Carolina Wealth Advisors LLC now owns 266 shares of the company’s stock worth $60,000 after purchasing an additional 209 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the transaction, the chairman now directly owns 306,752 shares in the company, valued at $74,283,064.32. This represents a 6.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 73,187 shares of company stock worth $17,790,912. Insiders own 15.80% of the company’s stock.

Cencora Price Performance

COR stock opened at $248.45 on Friday. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The firm has a market cap of $48.02 billion, a P/E ratio of 33.08, a PEG ratio of 1.54 and a beta of 0.49. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $253.27. The stock’s 50 day moving average price is $237.51 and its 200 day moving average price is $234.66.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were issued a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, November 15th. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.89%. Cencora’s payout ratio is 29.29%.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. UBS Group raised their price objective on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Wells Fargo & Company reduced their price target on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a research report on Friday, December 13th. Robert W. Baird lifted their target price on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Leerink Partners dropped their price target on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. Finally, Evercore ISI upped their price objective on Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $277.00.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.